Patrys

DR JAMES CAMPBELL

CEO & MANAGING DIRECTOR

(ASX:PAB)

◾ Company Name: Patrys ◾ Company ASX code: PAB ◾ Key areas: Novel antibody therapeutics for oncology ◾ Key Personnel: Dr James Campbell, CEO & Managing Director ◾ Locations: Melbourne, Australia ◾ Market Cap as of 15/09/22: $49.36M ◾ 52 Week share price as of 15 September: $0.019 - $0.047 ◾ Company Website: patrys.com

COMPANY PROFILE

Patrys’ deoxymab technology platform opens up new ways that antibodies can be used to treat cancer. This is because, unlike other antibodies, Patrys’ deoxymabs are able to enter cells and the cell nucleus where they can block the repair of damaged DNA.

Deoxymabs can also cross the bloodbrain barrier, a major advancement for antibody therapeutics. These properties enable deoxymabs to be used either alone or in conjunction with DNA damaging therapies (chemo drugs or radiation) to treat cancer.

It also allows deoxymabs to be used to target the delivery of various chemical payloads (drugs, imaging agents or oligonucleotides) across the blood-brain barrier or into the cell nucleus.

Patrys is currently developing two different forms of its deoxymabs. PAT-DX1, a small antibody fragment, has completed commercial scale manufacturing which is a key step for any antibody development program.

In coming months Patrys will complete the remaining preclinical studies required before PAT-DX1 starts human clinical trials in patients in H2 of 2023.

Patrys’ second deoxymab, PAT-DX3, is a full-sized antibody which is more typical of therapeutic antibodies. Patrys has established a cell line that can be used to manufacture PAT-DX3 and is currently developing a production process for this deoxymab.

The larger size of PAT-DX3 results in it having different pharmaceutical properties to PAT-DX1 which, in turn, means it can be used for different clinical applications. Furthermore, its larger size means that there are more places to attach various drugs or imaging agents that can then be delivered across the blood-brain barrier or into the cell nucleus.

Such constructs are called Antibody Drug Conjugates (or ADCs) and these are rapidly becoming one of the most commercially active areas in biopharmaceuticals.

Patrys’ deoxymabs have potential to be used in the clinic in three different ways: 1) as a stand-alone therapy in cancers that have pre-existing mutations in their DNA repair systems, 2) in conjunction with other agents that cause DNA damage such as chemotherapy and radiation therapy, or 3) as agents to deliver drugs across the blood-brain barrier or into the cell nucleus.

In preclinical studies Patrys has demonstrated that all three approaches appear to be viable opportunities. On their own or in combination with DNA-damaging therapies, deoxymabs have been able to significantly inhibit tumour growth and improve survival in animal models of human brain cancer, metastatic breast cancer, colon cancer, and pancreatic cancer.

Also in an animal model, PAT-DX3 successfully delivered a potent anticancer drug to tumour tissue where it significantly improved survival.

The unique properties of Patrys’ deoxymabs have attracted the interest of researchers, funding agencies and companies around the world.

Patrys has an ongoing collaboration with researchers at Yale University where the technology was developed, and across Australia.

The company also has a collaboration in place with ASX-listed company Imagion Biosciences to develop new imaging agents for brain cancer. Recently the Cure Brain Cancer Foundation Clinical Accelerator awarded $250,000 to researchers at the Telethon Kids Institute to study deoxymabs in brain cancers and researchers at the Olivia NewtonJohn Cancer Research Institute received $100,000 to study the use of deoxymabs to treat breast cancer.

Patrys has the expertise and the vision to successfully develop its deoxymab technology with a highly skilled team led by Dr James Campbell who has over 20 years of executive-level international biotech development and deal-making experience with transactions and capital raisings worth more than $400M.

KEY INVESTMENT HIGHLIGHTS

AUGUST 10, 2022: Study shows PATDX1 combined with radiation therapy significantly improves survival in animal models of brain cancer. AUGUST 26, 2022: Olivia Newton-John Cancer Research Institute awarded $100k grant to support investigation of Patrys’ deoxymab technology in controlling breast cancer tumour growth and metastasis. AUGUST 30, 2022: PAT-DX1 meets all specification tests, putting Patrys on a solid trajectory to initiate the planned phase 1 clinical trial in H2 CY2023.